Bliss GVS Pharma Reaches 52-Week High of Rs. 181.35 with 42.53% Annual Return

Bliss GVS Pharma, a small-cap player in the pharmaceuticals and drugs industry, has recently reached a new 52-week high of Rs. 181.35 on January 1, 2025. The stock has shown strong performance, outperforming its sector by 7.79% today. Over the past six days, Bliss GVS Pharma has experienced consecutive gains, accumulating a total return of 11.29%.

The stock’s intraday high of Rs. 181.35 reflects a 10.14% increase for the day. Additionally, Bliss GVS Pharma is currently trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a positive trend in its price movement.

In terms of annual performance, Bliss GVS Pharma has delivered a notable return of 42.53% over the past year, significantly outpacing the Sensex, which has recorded an 8.20% increase during the same period. The stock’s recent performance highlights its resilience and growth within the competitive pharmaceuticals sector.

Related Posts

  • Pharma
  • January 22, 2025
  • 87 views
Trump 2.0 Era: Pharma and Biotech Industries Eye Gains from Biosimilars and CDMO

As the “Trump 2.0 Era” begins in the United States, the world’s largest pharmaceutical market, attention is focused on its impact on the domestic pharmaceutical and biotech sectors. The industry…

  • Pharma
  • January 22, 2025
  • 102 views
Narcotics worth Rs 14 lakh seized in Jaipur, one arrested

Jaipur:  The Narcotics Control Bureau seized narcotic tablets and capsules worth Rs 14 lakh during an operation in Jaipur on Tuesday, an official said. The Narcotics Control Bureau (NCB) said…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Trump 2.0 Era: Pharma and Biotech Industries Eye Gains from Biosimilars and CDMO

Trump 2.0 Era: Pharma and Biotech Industries Eye Gains from Biosimilars and CDMO

Narcotics worth Rs 14 lakh seized in Jaipur, one arrested

Narcotics worth Rs 14 lakh seized in Jaipur, one arrested

DCA raids illegal de-addiction centre in Hanamkonda

DCA raids illegal de-addiction centre in Hanamkonda

CCI Approves Merger Of Nine Pharma Entities With Sequent Scientific

CCI Approves Merger Of Nine Pharma Entities With Sequent Scientific

Biocon urges govt to exempt cancer, rare-disease drugs from tax in Budget

Biocon urges govt to exempt cancer, rare-disease drugs from tax in Budget

Glenmark Pharma share rises 2% as unit launches blood clotting drug

Glenmark Pharma share rises 2% as unit launches blood clotting drug